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Antibodies to the Alzheimer disease (AD) ,%amyloid peptide (BAP) were used to identify /?AP precursor fragments in blood. The antibodies detected 
3 major polypeptides with apparent molecular weights (MW) of 47-64000 in Western blots of plasma derived clot proteins, but these proteins 
corresponded to human A-a, B-p and y-fibrinogen since they reacted with 2 different anti-fibrinogen antisera, and the anti-,!IAP and anti-fibrinogen 
antibodies recognized purified fibrinogen and fibrin. These data are significant for efforts to develop immunochemical ssays to diagnose and moni- 
tor the progression of AD. 
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1. INTRODUCTION 
Cerebral amyloid deposits in the core and corona of 
senile plaques (SPs) and in blood vessels (BVs) are pro- 
minent findings in Alzheimer’s disease (AD) and a 
number of other neurodegenerative disorders [l-3]. 
The major peptide in SPs and BVs is a recently describ- 
ed amyloidogenic protein fragment with an apparent 
molecular weight (MW) of 4000-5000 called the ,8- 
amyloid peptide @3AP) or A4 protein [4-61. The PAP 
appears to be derived from one or more of at least 3 
distinct precursor proteins with predicted amino acid 
(aa) lengths of 695, 751 and 770 aa, respectively [7-lo]. 
The predicted aa sequence of each of these fl-amyloid 
precursor proteins @APP), i.e. ,&APP695, pAPP-151 and 
PAPP770, is consistent with that of a membrane- 
associated glycoprotein resembling a cell surface recep- 
tor protein, and/or several different protease inhibitors 
[7- 131. The mRNAs encoding each ,0APP are present 
in both neural and non-neural cells, however the 
smallest ,&APP is much more abundant in brain than in 
other tissues [1,2,7- 151. Thus, it is conceivable that one 
or more of the PAPPs in peripheral tissues might 
undergo fragmentation to release the ,8AP into 
peripheral blood. Since the excess deposition of fl- 
amyloid fibrils in AD might reflect altered proteolysis 
of these flAPPs outside as well as within the brain, ef- 
forts have been made to identify and characterize 
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,8APP fragments that might circulate in peripheral 
blood and subsequently enter the brain [ 161. We report 
here on the characterization of low MW polypeptides, 
initially detected with anti-,&AP antibodies in normal 
human peripheral blood, which we then identified as 
human fibrinogen subunits. Specifically, a polyclonal 
antiserum and a monoclonal antibody (MAb) previous- 
ly raised to a peptide based on the first 28 aa of the #AP 
(AMY1-28 peptide), and shown to bind SPs and BV 
amyloid [ 171, recognized circulating human fibrinogen 
in peripheral blood and in the clots formed from 
plasma and purified fibrinogen. The immunobands 
detected by these 2 anti-PAP antibodies were identical 
to the triad of fibrinogen proteins recognized by 2 dif- 
ferent anti-fibrinogen antisera, and the latter antisera 
also were shown to bind the AMY1-28 peptide. 
2. MATERIALS AND METHODS 
2.1. Generation of monoclonal and poiyclonal antibodies 
Rabbit and mouse anti-PAP antisera and a panel of mouse anti- 
PAP MAbs were generated and screened using a synthetic PAP pep- 
tide designated here as AMY1-28. The immunochemical and im- 
munohistochemical properties of these antibodies have been 
described in detail elsewhere [17]. Purified human fibrinogen and an 
antiserum specific for human fibrinogen were purchased from Sigma 
Chemical Company. Another antiserum to human fibrinogen was 
purchased from Accurate Chemicals. 
2.2. ELISA, gel electrophoresis and immunoblotting 
Procedures for ELISA, gel electrophoresis and Western blotting 
have been described extensively in past publications [ 17-211. 
2.3. Preparation of plasma, serum and blood clot proteins 
Blood was collected in blue top Vacutainer tubes (Becton Dickin- 
son) containing sodium citrate. These tubes are used to harvest 
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samples for studies of the coagulation properties of human blood. 
The samples of human blood were then spun in a clinical centrifuge 
to separate plasma from cellular components, and EDTA was added 
to the plasma fraction to achieve a f mM final conc~tration of ED- 
TA. Serum was prepared from aliquots of the plasma fraction by the 
addition of bovine thrombin (Sigma Chemical Company) in a drop- 
wise manner until a clot formed, and the serum was separated from 
the clot by centrifugation in a microfuge for 3 min. To obtain 
purified clot proteins, EDTA was added to an aliquot of plasma to 
a final concentration of 5 mM, followed by the addition of approx- 
imately 100~1 of bovine thrombin to 750~1 aliquots of plasma. 
Alternatively, thrombin was added in a dropwise manner to a solu- 
tion of purified fibrinogen (2 mglml) to induce clot formation. The 
formed clot was placed on a fine nylon mesh overlaid on a filter paper 
to withdraw residual serum, and the clot was washed in 20 ml of 
PBS. The clot was then gently lifted from the mesh with a forceps and 
homogenized in 750 pl of sample buffer and boiled for IO min prior 
to electrophoresis. Sample buffer also was separately added to equal 
volumes of serum and plasma aliquots, and each was boiled for 
10 min prior to electrophoresis. Typically, 6-10 ~1 of these samples 
were run in each lane of a 15 well comb. 
2.4. Analysis of human brain tissue and rat ~he~~~ro~ocytoma 
Samples of normal human, AD and Down’s syndrome brain tissue 
as well as PC12 cells [21] also were examined with the anti-@AP and 
anti-fibrinogen antibodies in Western blots using methods similar to 
those reported elsewhere from this laboratory (see [17-211 and cita- 
tions therein). The diagnostic assessment of the human brain tissues 
has been described [17-201. 
3. RESULTS AND DISCUSSION 
The anti-AMY’-28 antisera and 12 MAbs raised to 
AMY’-*’ were screened for reactivity against normal 
human plasma by Western blot analysis. One of the an- 
tisera and 4 of the MAbs recognized a complex of in- 
tensely labeled immunobands in plasma. The antiserum 
and one of the MAbs (an IgGl designated AMY 33) 
were selected for the further ch~a~erization of these 
immunobands. As described previously, both this an- 
tiserum and the AMY 33 MAb strongly stained AD and 
control SPs and BV amyloid deposits, and both were 
specific for AMYlm2* by ELISA, but failed to bind two 
unrelated peptides [17]. By Western blot analysis, 
several immunoreactive bands were demonstrated in 
normal human plasma from volunteers in the 3rd 
through 6th decades of life. In clot prepared from the 
plasma, the ,&AP antibodies detected 3 prominent im- 
munobands with a MW of 45000-64000 that were not 
present in serum generated from the same plasma frac- 
tion. In Coomassie blue stained gels of the clot, 3 
discrete protein bands with apparent MWs of 
45000-64000 were among the most abundant species 
noted (Fig. lA, lanes 1 and 2), and all 3 of these 
pol~eptides were immunoreactive with the anti-PAP 
MAb (lanes 1 and 2 in Fig. 1B) and the antiserum, 
although the antiserum recognized these proteins to a 
lesser extent than the anti-PAP MAb (data not shown). 
These findings led us to conclude that the immunoreac- 
tive species identified here were involved in clot forma- 
tion, especially since they were removed completely 
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Fig. 1. Photo~aphs of plasma derived clot samples (lanes 1 and 2 in 
A and B), purified human fibrinogen (lanes 3 in A and B) and clot 
proteins derived from purified human fibrinogen (lanes 4 in A and B) 
that were separated by SDS-PAGE and stained with Coomassie blue 
(A) or transferred to nitrocellulose and probed with AMY 33 (B). The 
MW standards shown in lane 5 of panel A include, from top to 
bottom, ,%galactosidase, phosphorylase B, bovine serum albumin, 
egg albumin and carbonic anhydrase. 
from serum during the clotting process. Notably, only 
a few plasma proteins exhibit these properties, among 
which fibrinogen is the most abundant plasma clotting 
factor (200-400 mg/lOO ml of plasma) (see [22-241 
and additional references therein). Further, fibrin, 
which is derived from plasma fibrinogen as a result of 
thrombin mediated cleavage of small fibrinopeptides 
from intact fibrinogen, is the princip~ clot protein. Ac- 
cordingly, we then compared the i~unobands pro- 
duced by the anti-PAP antibodies with those detected 
by two different anti-fibrinogen antisera in similar 
Western blots of human plasma derived blood clots. 
Not surprisingly, the anti-fibrinogen antibodies pro- 
duced a triplet of immunobands that were identical to 
those produced by the anti-@AP antibodies when they 
were used to probe the same clot proteins (data not 
shown). A commercial preparation of human 
fibrinogen was then used as a test antigen in Western 
blots, and both the anti-AMY’-*’ antiserum and the 
MAb labeled three prominent immunobands with an 
apparent MW of 47 000,560OO and 64000 (see lane 3 in 
Fig. IB) exactly like both of the anti-fibrinogen an- 
tisera. Finally, clots prepared from the purified human 
fibrinogen by the addition of the serine protease throm- 
bin also contained 3 similar bands that were labeled by 
both anti-PAP antibodies (see lane 4 in Fig. 1B). 
Human fibrinogen polypeptides are among the most 
thoroughly characterized of human proteins, and they 
are known to be composed of 3 subunits referred to as 
the A-a, B-P and y subunits. By SDS-PAGE, they have 
apparent MWs of 47000,560OO and 63 500, respective- 
ly 122-241. Thus, the MWs of the bands detected in 
Western blots of the clot proteins and in the fibrinogen 
blots with the anti-PAP and anti-fibrinogen antibodies 
were identical to those ascribed to each of the 3 human 
fibrinogen subunits. Although the aa sequences of 
these fibrinogen subunits differ, they are highly 
homologous 122-24). Thus, it is not surprising that the 
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AMY’-‘* antiserum and the AMY 33 MAb recognized 
all 3 of ‘these fibrinogen subunits rather than only one 
or two of them. 
In order to quantitate the relative affinity of these 
cross-reactions, ELISA was performed using serial 
dilutions of the AMY’-‘* peptide and purified 
fibrinogen. In these studies, dilutions of test antigen 
ranging from 0.005 to 5.0 @g/well were applied to dif- 
ferent wells of 96 well ELISA plates. Subsequently, 
various dilutions of the AMY 33 MAb (ranging from 
undiluted supernatant o dilutions of 1: 100) as well as 
of the anti-PAP and anti-fibrinogen antisera (i.e. 
1: 100, 1: 1000, 1: 10000) were applied to the ELISA 
plates. ELISA was recorded as positive if an optical 
density higher than background {i.e. >O.lO) was ob- 
tained at a wavelength of 450 nm as described 
elsewhere [17-211. The undiluted AMY 33 supernatant 
produced a positive ELISA against 0.02,~g of the 
AMY’-‘* peptide, whereas >60-fold more (i.e. at least 
1.25 pg) of the purified fibrinogen sample was needed 
to achieve a positive ELISA with the same MAb used 
under the same conditions. Further, at a dilution of 
1: 100, the AMY 33 MAb was able to detect as little as 
0.75 /cg of the AMYrm2’ peptide, but it failed to yield 
a positive ELISA result even when tested using 5.0 /rg 
of the purified fibrinogen sample. The anti$AP an- 
tiserum did not recognize human fibrinogen at the dilu- 
tions used here, e.g., at a dilution of 1: 1000 the 
antiserum detected 0.02pg of the AMYrW2* peptide, 
but did not bind any amount of ~brinogen. As might 
be anticipated, the anti-fibrinogen antisera exhibited a 
higher affinity for purified fibrinogen than for the PAP 
peptide. For example, at a dilution of 1: 100 the anti- 
fibrinogen antisera detected 0.625 pg of the AMY’-‘* 
peptide, but the same amount of fibrinogen yielded a 
positive ELISA when the same antisera were used at a 
dilution of 1: 10000. These results are summarized in 
Table I. 
normal human, AD or Down’s syndrome brain tissues, 
or in the rat PC12 cells. The AMY 33 MAb and all 3 
antisera produced a highly complex but similar profile 
of immunobands, and at least 4 roughly equivalent im- 
munobands were detected by these antibodies in the 
preparations described above (compare Fig. 2A and 
23). 
The specificity of the cross-reaction between AMY 
33 and fibrinogen was further substantiated in control 
experiments wherein we absorbed out the reactivity of 
AMY 33 for the PAP and senile plaque amyloid with 
the AMYre2* peptide, as described earlier [171, and 
showed that the absorbed MAb failed to recognize 
fibrinogen (data not shown). In addition, 3 other MAbs 
(RM093, RMS12, RM055) with an IgGl isotype that 
were raised to and shown to be specific for neurofila- 
ment proteins [l&19] did not bind to fibrinogen (data 
not shown). Finally, other polyclona antisera specific 
for components of senile plaques (i.e. paired helical 
filament antigens, a- 1 -anti-chymotrypsin) also did not 
demonstrate any affinity for fibrinogen (data not 
shown). 
A 6 
V-c** 
Additional immunoblot studies were conducted with 
the AMY’-28 antibodies and the anti-fibrinogen an- 
tisera to determine if similar immunobands were 
detected by both types of antibodies in homogenates of 
Table I 
Test antigen AMY 33 MAb AMY AS Anti-fibrinogen AS 
1: 1000 
Undiluted 1: 100 1:lOo 1:10060 
AMY’-” 0.02 0.75 0.02 0.625 5.0 
Fibrinogen 1.25 NR NR 0.01 0.625 
This table summarizes the quantitative ELISA data on the relative 
affinity of the anti-@AP and anti-fibrinogen antibodies for the 
AMY’-‘* peptide or purified human fibrinogen as described in the 
text. The lowest amount [in fig) of AMY’-** or fibrinogen detected 
by the AMY 33 MAb, the AMY’-28 antiserum (AS) or the anti- 
fibrinogen antiserum at the dilutions listed below each antibody are 
shown here. NR, no reactivity with as much as 5.0 gg of the purified 
1 2 3 1 2 3 
Fig. 2. Western blots of Triton X-LOO soluble (lanes 1 in A and B) and 
insoluble (Ianes 2 in A and B) homogenates of PC12 ceils, as well as 
a Triton X-100 insohtble fraction from a Down’s syndrome brain 
homogenate. Tire blots were probed with an anti-fibrinogen 
antiserum diluted I : 1000 (A) or with the anti-PAP antiserum at a 
dilution of 1: 100 (B). Note that the banding pattern is not identical 
in both blots, but a number of immunobands in each lane display the 
fibrinogen same electrophoretic mobility. 
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The studies reported here provide evidence for a 
significant cross-reaction between anti-PAP antibodies 
and intact fibrinogen, as well as for the relatively large 
fibrinogen-derived cleavage products (i.e. fibrin pro- 
teins) in blood clots. In addition, we demonstrated a 
reiprocal cross-reaction between anti-fibrinogen an- 
tibodies and a PAP peptide, i.e. the AMY ‘-” peptide. 
Although the AMY33 MAb recognized purified 
fibrinogen and crude fibrin prepared from human 
plasma in both ELISA and Western blot analyses, the 
anti-AMY ‘-” polyclonal antiserum recognized 
fibrinogen in plasma and clots far less intensely in 
Western blots and it failed to detect fibrinogen in 
ELBA. In contrast, the anti-fibrinogen antiserum 
recognized the AMY’-” peptide by ELISA, and, like 
the anti-AMY’-28 antiserum and MAb, it produced 
similar immunobands in homogenates of human brain 
tissues as well as in homogenates of PC12 cells. 
Although ‘molecular mimicry’ among unrelated 
polypeptides with homologous or identical aa se- 
quences is well known [ZS], the cross reactions describ- 
ed here do not reflect aa sequence identity between the 
PAP and fibrinogen. They also are unlikely to reflect 
homologies between epitopes that result from similar 
posttranslation modifications such as glycosylation 
and/or phosphorylation because the putative sites at 
which the ,&APPs are glycosylated and phosphorylated 
he outside thePAP or A4 region of these precursor pro- 
teins [7-10,261. Further, the synthetic AMY’-=* pep- 
tide is neither a glycopeptide nor a phosphopeptid~. 
Therefore, we ascribe these cross-reactions to confor- 
mational homologies between the ,&AP and fibrinogen. 
Since the secondary structure of the PAP peptide 
studied here has been well characterized by circular 
dichroism [27], and a similar peptide has been shown 
by electron microscopy to form amyloid-like fibrils 
[28], the underlying structure recognized by the an- 
tibodies described here may closely approximate the 
conformation that the AMY’-28 peptide has been pro- 
posed to assume in a microenvironment which pro- 
motes hydrogen bond formation (i.e. a-helix/,&turn/ 
unordered/,&sheet/unordered) [27]. Regardless of the 
molecular basis for these cross-reactions, the observa- 
tions reported here are especially significant for future 
efforts to develop immunological assays to diagnose or 
monitor the progression of AD using peripheral blood 
as well as neural and non-neural tissues and fluids 
[16,29]. Such efforts could be impeded if anti-PAP 
and/or anti-,&APP antibodies cross-react not only with 
fibrinogen, but also with other circulating human 
peripheral blood proteins because such cross-reactions 
would obscure potential differences in the levels of cir- 
culating ,&APPs or @APP peptides when control and 
AD subjects are screened. Indeed, such cross-reactions 
may account for the absence of differences in cir- 
culating plasma levels of ,&APPs in a previous study of 
controls and patients with AD and Down’s syndrome 
46 
using radioimmunoassay and antisera raised to a car- 
boxy terminal PAPP peptide [ 161. 
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